Barclays’s Repligen RGEN Stock Holding History

Barclays’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-60,000	Closed	-$7.07M	–	5577
2026 Q1	$7.07M	Hold	60,000	–	–	﹤0.01%	1623
2025 Q4	$9.83M	Buy	+60,000	New	+$9.4M	﹤0.01%	1688
2025 Q3	–	Sell	-20,000	Closed	-$2.49M	–	5693
2025 Q2	$2.49M	Buy	+20,000	New	+$2.55M	﹤0.01%	2688
2024 Q3	–	Sell	-121,000	Closed	-$15.3M	–	5438
2024 Q2	$15.3M	Sell	121,000 -257,100	-68%	-$40.3M	﹤0.01%	1030
2024 Q1	$69.5M	Buy	+378,100	New	+$72M	0.02%	489
2015 Q2	–	Sell	-90,000	Closed	-$2.7M	–	7170
2015 Q1	$2.7M	Sell	90,000 -185,000	-67%	-$4.8M	﹤0.01%	2040
2014 Q4	$5.22M	Buy	+275,000	New	+$6.15M	0.01%	1670

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Barclays's RGEN Position: Q2 2026 in Review

Barclays reduced its Repligen (RGEN) stake by 20% in Q2 2026, selling an estimated $4.7M and leaving 155,745 shares worth $21.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

Barclays first reported a position in RGEN in Q2 2013 and has held it in 53 quarters since. The position peaked at $34.3M in Q3 2025. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

Barclays held 155,745 shares of Repligen worth $21.2M as of Q2 2026.
Barclays sold 38,271 Repligen shares in Q2 2026, an estimated $4.7M.
Repligen made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1100 holding.
Barclays first reported a position in Repligen in Q2 2013 and has held it in 53 quarters since.
Barclays's Repligen position peaked at $34.3M in Q3 2025.
482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.